LEADER 01707nam  2200553Ia 450 
001 9910789744603321
005 20200520144314.0
010   $a1-61122-360-1
035   $a(CKB)2670000000129722
035   $a(EBL)3018688
035   $a(SSID)ssj0000689406
035   $a(PQKBManifestationID)11942934
035   $a(PQKBTitleCode)TC0000689406
035   $a(PQKBWorkID)10618053
035   $a(PQKB)10509578
035   $a(MiAaPQ)EBC3018688
035   $a(Au-PeEL)EBL3018688
035   $a(CaPaEBR)ebr10661626
035   $a(OCoLC)761307745
035   $a(EXLCZ)992670000000129722
100   $a20100827d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aGeneric drugs$b[electronic resource] $ethe pay-for-delay problem /$fChristina M. Curtin, editor
210   $aNew York $cNova Biomedical/Nova Science Publishers$dc2011
215   $a1 online resource (138 p.)
225 1 $aPublic health in the 21st century
300   $aDescription based upon print version of record.
311   $a1-61122-071-8 
320   $aIncludes bibliographical references and index.
410  0$aPublic health in the 21st century series.
606   $aGeneric drugs$xPrices
606   $aDrugs$xPrices
606   $aPharmaceutical industry$zUnited States
615  0$aGeneric drugs$xPrices.
615  0$aDrugs$xPrices.
615  0$aPharmaceutical industry
676   $a338.4/361510973
701   $aCurtin$b Christina M$01497719
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910789744603321
996   $aGeneric drugs$93722952
997   $aUNINA